| Dr Watcharasarn Rattananan, MD | |
|
201 S Gibson Rd Apt 1208, Henderson, NV 89012-2660 | |
| (615) 345-5400 | |
| (888) 468-6603 |
| Full Name | Dr Watcharasarn Rattananan |
|---|---|
| Gender | Male |
| Speciality | Psychiatry & Neurology - Clinical Neurophysiology |
| Location | 201 S Gibson Rd Apt 1208, Henderson, Nevada |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1760612659 | NPI | - | NPPES |
| MD2019-0793 | Other | NM | NEW MEXICO MEDICAL BOARD |
| Entity Name | Remote Neuromonitoring Physicians Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1124253075 PECOS PAC ID: 1355495961 Enrollment ID: O20180521000858 |
News Archive
Synexus has completed a phase II study for the European biotech, Creabilis, recruiting 26 patients in the UK to the psoriasis trial of its CT327 lead product in just 2 weeks, as part of an international proof-of-concept study. The company delivered the targeted number of patients well within the agreed timelines and budget.
California Insurance Commissioner Dave Jones criticized Blue Shield of California for an "unreasonable" rate hike affecting about 81,000 individual policyholders. ... But he and other state officials don't have the authority to reject changes in premiums. Jones said the latest rate hike amounted to an average increase of 32 percent over a two-year period (Terhune, 1/7).
Phase 2 trial results for elinogrel, a novel antiplatelet agent available in both intravenous and oral formulations, were presented here today.
Overdiagnosis poses a significant threat to human health by labeling healthy people as sick and wasting resources on unnecessary care, warns Ray Moynihan, Senior Research Fellow at Bond University in Australia, in a feature published on bmj.com today.
› Verified 1 days ago
| Entity Name | Sentient Physicians Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1306204805 PECOS PAC ID: 2668764333 Enrollment ID: O20190227002035 |
News Archive
Synexus has completed a phase II study for the European biotech, Creabilis, recruiting 26 patients in the UK to the psoriasis trial of its CT327 lead product in just 2 weeks, as part of an international proof-of-concept study. The company delivered the targeted number of patients well within the agreed timelines and budget.
California Insurance Commissioner Dave Jones criticized Blue Shield of California for an "unreasonable" rate hike affecting about 81,000 individual policyholders. ... But he and other state officials don't have the authority to reject changes in premiums. Jones said the latest rate hike amounted to an average increase of 32 percent over a two-year period (Terhune, 1/7).
Phase 2 trial results for elinogrel, a novel antiplatelet agent available in both intravenous and oral formulations, were presented here today.
Overdiagnosis poses a significant threat to human health by labeling healthy people as sick and wasting resources on unnecessary care, warns Ray Moynihan, Senior Research Fellow at Bond University in Australia, in a feature published on bmj.com today.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Watcharasarn Rattananan, MD 3 Maryland Farms Ste 200, Brentwood, TN 37027-5005 Ph: (615) 345-5400 | Dr Watcharasarn Rattananan, MD 201 S Gibson Rd Apt 1208, Henderson, NV 89012-2660 Ph: (615) 345-5400 |
News Archive
Synexus has completed a phase II study for the European biotech, Creabilis, recruiting 26 patients in the UK to the psoriasis trial of its CT327 lead product in just 2 weeks, as part of an international proof-of-concept study. The company delivered the targeted number of patients well within the agreed timelines and budget.
California Insurance Commissioner Dave Jones criticized Blue Shield of California for an "unreasonable" rate hike affecting about 81,000 individual policyholders. ... But he and other state officials don't have the authority to reject changes in premiums. Jones said the latest rate hike amounted to an average increase of 32 percent over a two-year period (Terhune, 1/7).
Phase 2 trial results for elinogrel, a novel antiplatelet agent available in both intravenous and oral formulations, were presented here today.
Overdiagnosis poses a significant threat to human health by labeling healthy people as sick and wasting resources on unnecessary care, warns Ray Moynihan, Senior Research Fellow at Bond University in Australia, in a feature published on bmj.com today.
› Verified 1 days ago
Dr. Leo R Germin, MD Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 1691 West Horizon Ridge Parkway, Henderson, NV 89012 Phone: 702-804-1212 Fax: 702-804-1273 | |
Rose Marie Gustilo, MD Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 2518 Darda St, Henderson, NV 89044 Phone: 702-617-3597 | |
Mokhtar Boukhari, DO Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 10001 S Eastern Ave Ste 200, Henderson, NV 89052 Phone: 702-790-1521 | |
Dr. Romina Shirka, D.O. Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 102 Appia Pl, Henderson, NV 89011 Phone: 615-346-8182 Fax: 615-829-8970 | |
Zeshan Mudasir, D.O. Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 10624 S Eastern Ave # A-955, Henderson, NV 89052 Phone: 702-800-5393 Fax: 702-407-7016 | |
Kelli M Gandy, APRN-PMHNP Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 211 W Atlantic Ave, Henderson, NV 89015 Phone: 702-823-4300 | |
Chau Pham, Psychiatry & Neurology Medicare: Medicare Enrolled Practice Location: 1020 S Boulder Hwy, Henderson, NV 89015 Phone: 702-791-9030 |